Abstract
Vulvovaginal candidiasis (VVC) is a global health problem affecting ∼75% of women at least once in their lifetime. Here we examined the epidemiology of VVC in a patient cohort to identify the causative organisms associated with VVC. Biofilm-forming capacity and antifungal sensitivity profiles were also assessed. We report a shifting prevalence of Candida species with heterogeneous biofilm-forming capacity, which is associated with altered antifungal drug sensitivity.
Keywords:
Candida; biofilm; fluconazole; vulvovaginal candidiasis.
Copyright © 2017 American Society for Microbiology.
MeSH terms
-
Antifungal Agents / therapeutic use*
-
Biofilms / drug effects*
-
Biofilms / growth & development
-
Candida albicans / drug effects*
-
Candida albicans / isolation & purification
-
Candida glabrata / drug effects
-
Candida glabrata / isolation & purification
-
Candida parapsilosis / drug effects
-
Candida parapsilosis / isolation & purification
-
Candida tropicalis / drug effects
-
Candida tropicalis / isolation & purification
-
Candidiasis, Vulvovaginal / drug therapy*
-
Candidiasis, Vulvovaginal / epidemiology
-
Candidiasis, Vulvovaginal / microbiology*
-
Drug Resistance, Fungal
-
Female
-
Fluconazole / therapeutic use*
-
Humans
-
Microbial Sensitivity Tests
-
Vaginal Smears
Substances
-
Antifungal Agents
-
Fluconazole